Published online before print September 22, 2005, doi: 10.1161/01.RES.0000187500.24964.7A
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 American Heart Association, Inc.
Clinical Research |
Mineralocorticoid Receptor Blocker Increases Angiotensin-Converting Enzyme 2 Activity in Congestive Heart Failure Patients
From the Lipid Research Laboratory (S.K., A.G.-L., M.K., E.P., S.H., T.H., R.K.), Rambam Medical Center as well as the Bruce Rappaport Family Institute for Research in the Medical Sciences and the Faculty of Medicine; Department of Vascular Surgery and Transplantation, Rambam Medical Center, Haifa, Israel; and Department of Physiology and Biophysics (Z.A.), The Bruce Rappaport Institute for Research in the Medical Sciences and the Faculty of Medicine, Technion, Israel.
Correspondence to Prof Shlomo Keidar, Internal Medicine Department "A", Rambam Medical Center, 31096 Haifa, Israel. E-mail skeidar{at}rambam.health.gov.il
Aldosterone plays an important role in the pathophysiology of congestive heart failure (CHF), and spironolactone improves cardiovascular function and survival rates in patients with CHF. We hypothesized that the mineralocorticoid receptor blockade (MRB) exerted its beneficial effects by reducing oxidative stress and changing the balance between the counter-acting enzymes angiotensin-converting enzyme (ACE) and ACE2. Monocyte-derived macrophages were obtained from 10 patients with CHF before and after 1 month of treatment with spironolactone (25 mg/d). Spironolactone therapy significantly (P<0.005) reduced oxidative stress, as expressed by reduced lipid peroxide content, superoxide ion release, and low-density lipoprotein oxidation by 28%, 53%, and 70%, respectively. Although spironolactone significantly (P<0.01) reduced macrophage ACE activity by 47% and mRNA expression by 53%, ACE2 activity and mRNA expression increased by 300% and 654%, respectively. In mice treated for 2 weeks with eplerenone (200 mg · kg–1 · d–1), cardiac ACE2 activity significantly (P<0.05) increased by 2-fold and was paralleled by increased ACE2 activity in macrophages. The mechanism of aldosterone antagonist action was studied in mouse peritoneal macrophages (MPMs) in vitro. Although ACE activity and mRNA were significantly increased by 250 nmol/L aldosterone, ACE2 was significantly reduced. Cotreatment with eplerenone (2 µmol/L) attenuated these effects. In MPM obtained from p47 knockout mice, where NADPH oxidase is inactive, as well as in control MPMs treated with NADPH oxidase inhibitor, aldosterone did not increase ACE or decrease ACE2. MRB reduced oxidative stress, decreased ACE activity, and increased ACE2 activity, suggesting a protective role for MRB by possibly increasing generation of angiotensin (1–7) and decreasing formation of angiotensin II. These effects are mediated, at least in part, by NADPH oxidase.
Key Words: heart failure • mineralocorticoid receptor blockade • ACE2
This article has been cited by other articles:
 |
|
 |
|
  Z. Kassiri, J. Zhong, D. Guo, R. Basu, X. Wang, P. P. Liu, J. W. Scholey, J. M. Penninger, and G. Y. Oudit Loss of Angiotensin-Converting Enzyme 2 Accelerates Maladaptive Left Ventricular Remodeling in Response to Myocardial Infarction Circ Heart Fail, September 1, 2009; 2(5): 446 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Thomson, M. P. Frenneaux, and J. C. Kaski Antioxidant treatment for heart failure: friend or foe? QJM, May 1, 2009; 102(5): 305 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Levy, Y. Yagil, M. Bursztyn, R. Barkalifa, S. Scharf, and C. Yagil ACE2 expression and activity are enhanced during pregnancy Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2008; 295(6): R1953 - R1961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mulder, V. Mellin, J. Favre, M. Vercauteren, I. Remy-Jouet, C. Monteil, V. Richard, S. Renet, J. P. Henry, A. Y. Jeng, et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone Eur. Heart J., September 1, 2008; 29(17): 2171 - 2179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Epelman, W.H. W. Tang, S. Y. Chen, F. Van Lente, G. S. Francis, and S. Sen Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart Failure: Insights Into the Endogenous Counter-Regulatory Pathway of the Renin-Angiotensin-Aldosterone System J. Am. Coll. Cardiol., August 26, 2008; 52(9): 750 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yamada, M. Kushibiki, T. Osanai, H. Tomita, and K. Okumura Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization Cardiovasc Res, July 1, 2008; 79(1): 169 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Brosnihan, J. B. Hodgin, O. Smithies, N. Maeda, and P. Gallagher Tissue-specific regulation of ACE/ACE2 and AT1/AT2 receptor gene expression by oestrogen in apolipoprotein E/oestrogen receptor-{alpha} knock-out mice Exp Physiol, May 1, 2008; 93(5): 658 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. S. Santos, A. J. Ferreira, and A. C. Simoes e Silva Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis Exp Physiol, May 1, 2008; 93(5): 519 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Brandes Avoiding Vicious Circles: Mineralocorticoid Receptor Antagonism Prevents Vascular Oxidative Stress Early After Myocardial Infarction Hypertension, November 1, 2007; 50(5): 842 - 843. [Full Text] [PDF]
|
|
|
|
|
|
M. C. Chappell Emerging Evidence for a Functional Angiotensin-Converting Enzyme 2-Angiotensin-(1-7)-Mas Receptor Axis: More Than Regulation of Blood Pressure? Hypertension, October 1, 2007; 50(4): 596 - 599. [Full Text] [PDF]
|
|
|
|
|
|
G. Y. Oudit, Z. Kassiri, M. P. Patel, M. Chappell, J. Butany, P. H. Backx, R. G. Tsushima, J. W. Scholey, R. Khokha, and J. M. Penninger Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice Cardiovasc Res, July 1, 2007; 75(1): 29 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Keidar, A. Strizevsky, A. Raz, and A. Gamliel-Lazarovich ACE2 activity is increased in monocyte-derived macrophages from prehypertensive subjects Nephrol. Dial. Transplant., February 1, 2007; 22(2): 597 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Keidar, M. Kaplan, and A. Gamliel-Lazarovich ACE2 of the heart: From angiotensin I to angiotensin (1-7) Cardiovasc Res, February 1, 2007; 73(3): 463 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Grobe, A. P. Mecca, H. Mao, and M. J. Katovich Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2417 - H2423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A.S. Santos, C. H. Castro, E. Gava, S. V.B. Pinheiro, A. P. Almeida, R. D. de Paula, J. S. Cruz, A. S. Ramos, K. T. Rosa, M. C. Irigoyen, et al. Impairment of In Vitro and In Vivo Heart Function in Angiotensin-(1-7) Receptor Mas Knockout Mice Hypertension, May 1, 2006; 47(5): 996 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Armanini, C. Fiore, L. A Calo, S. Takai, and M. Miyazaki Mononuclear Leukocyte Mineralocorticoid Receptors * Response Hypertension, February 1, 2006; 47(2): e4 - e5. [Full Text] [PDF]
|
|